UNSPSC 51314336: Chlorpheniramine/dextromethorphan/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314336 Chlorpheniramine/dextromethorphan/pseudoephedrine is a Commodity code whose recent state and local opportunities reflect broader pharmaceutical procurement activity rather than the narrow combination drug product named in the code. The work actually being solicited under this code spans emergency-response medications (naloxone), generic multi-source pharmaceuticals distributed through licensed wholesalers, and direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing consortia administering shared pharmaceutical supply agreements. The scope encompasses both end-use procurement by local community health facilities and upstream contracting with pharmaceutical manufacturers and distributors to establish pricing, availability, and delivery terms for state and local government systems.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking annual supply of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to its Community Health Building, with bid response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026; MMCAP contracts serve participating state and local facilities across multiple states including Oregon and require vendor supply through three authorized wholesalers with pricing weighted 75 percent in evaluation.